SEC filings

• Management to host Q2 2026 update at 5PM ET / 2PM PT, today.

Los Angeles, CA -- August 20, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.

• Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.
• Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.
• The new process produced approximately 67% more NCT per liter than the previously announced 100-liter pilot run.
• Reaction time was reduced by over 80%, allowing substantially more product to be produced in less time.
• The improvements support a more scalable and efficient manufacturing process as eXoZymes prepares for technology transfer to future commercial partners.

Los Angeles, CA -- August 18, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced significant improvements to its manufacturing process for N-trans-caffeoyltyramine (“NCT”), marking a significant step toward scalable commercial production.

Los Angeles, CA -- August 11, 2026 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.